Advertisement

Topics

Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials

10:30 EDT 20 Jun 2017 | Healio

RTH258 for wet age-related macular degeneration met its primary and key secondary endpoints in two phase 3 studies, according to a Novartis press release.The HAWK and HARRIER trials studied the non-inferiority of RTH258 (brolucizumab, 6 mg) vs. Eylea (aflibercept, Regeneron) in regards to change in best corrected visual acuity from baseline to week 48 and average mean change between week 36 and week 48. These endpoints were met with significant P values.

Original Article: Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials

NEXT ARTICLE

More From BioPortfolio on "Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...